Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy's launches generic Protonix in US, Sun to recommence supplies

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories has launched in the US pantoprazole sodium 20mg and 40mg delayed-release tablets, generic versions of Nycomed's Protonix tablets, even as another Indian firm, Sun Pharmaceutical Industries, said that it expects to re-enter the market with its version.

You may also be interested in...



India Lockdown: Early Signs of Manufacturing Strains But Resolutions Underway

Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’

India Bars Exports Of Hydroxychloroquine With Some Exceptions

India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.

Alembic: Enough Inventory, China API Supplies Heading Back To Normalcy

Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC011573

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel